Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor David Bennett is leading a new national research consortium to investigate neuropathic pain.

PAINSTORM (Partnership for Assessment and Investigation of Neuropathic Pain: Studies Tracking Outcomes, Risks and Mechanisms) is part of the new Advanced Pain Discovery Platform, a major investment led by the Medical Research Council and supported by the UKRI Strategic Priorities Fund and Versus Arthritis. It will involve NDCN colleagues Professor David Bennett, Professor Irene Tracey, Associate Professor Annina Schmid, Clinical Lecturer Andreas Themistocleous, Research Co-investigator Georgios Baskozos, and Project Manager Mathilde Pascal.

I believe that PAINSTORM, both due to its scale and embedded interdisciplinary interactions, can bring a perspective to neuropathic pain which has previously not been possible even on a global scale. I look forward to working with all our academic partners, industry and our patient partners, ultimately to make a positive impact on the lives of those living with neuropathic pain. - Professor David Bennett, Nuffield Department of Clinical Neurosciences

The Oxford team will be working closely with patient partners; academic colleagues in Dundee, Aberdeen, Imperial, King's College London and Ghent; and industry partners Lilly and AstraZeneca. The aim is that this inter-disciplinary collaboration will help translate the research into effective, multifaceted interventions.

Neuropathic pain has a major impact on quality of life, affecting 8% of the population. It is caused by damage to the sensory nervous system, through conditions such as diabetes, chemotherapy and HIV. Current management options are only effective in a small subgroup of patients, and much of the research and clinical management in this area is separate rather than being interdisciplinary.

PAINSTORM will use a broad range of approaches cutting across traditional disciplinary boundaries, to uncover the causes of neuropathic pain and understand how they interact, from molecule to society. The focus will be on studying people at risk of neuropathic pain and following their progress over time.

PAINSTORM will be investigating the pathophysiological mechanisms underlying neuropathic pain, improving outcome measures/pain biomarkers and ultimately translating this into better management of neuropathic pain. The team hope to improve the targeting of existing analgesics as well as identify new therapeutic targets and optimise psychological and physical interventions.

Similar stories

Study reveals association between diagnosis of a neuropsychiatric condition and severe outcome from COVID-19 infection, and other severe acute respiratory infections

New research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Visit from the Sir Jules Thorn Charitable Trust

Earlier this month, we were delighted to welcome the Director of the Sir Jules Thorn Charitable Trust, Richard Benson, and its Chair of Trustees, Liz Charal.

Oxford receives £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. Our department will play a major role.